BMO Capital maintains its Outperform rating on Primo Brands Corporation (PRMB) despite lowering its price target, citing strong premium brand growth and a long-term recovery path for its direct-to-consumer segment.
FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.
Despite promising mid-stage clinical data and billion-dollar sales potential for its mRNA pipeline, Arcturus Therapeutics (ARCT) is trading near its cash value—a signal the market is assigning near-zero odds to its success. This stark disconnect has analysts debating whether the biotech firm is a glaring mispricing or a high-risk bet.
Advance Auto Parts (NYSE:AAP) remains a favored pick among hedge funds, even as Wall Street analysts offer conflicting price targets and ratings ahead of anticipated 2026 demand growth.
A 68-year-old Cincinnati woman and her two adult children perished in a fast-moving house fire last month, with officials describing the conditions as 'not survivable.'
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
A couple approaching retirement with $1 million in savings and $42,000 in expected Social Security benefits questions if a $90,000 annual budget is feasible. Financial experts weigh the critical factors—from tax implications to withdrawal rates—that will determine the sustainability of their plan.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Africa's used vehicle market is on track to expand at nearly 7% annually, approaching a $200 billion valuation by 2033, as demand for affordable personal transport surges across the continent.
A major protest against U.S. Immigration and Customs Enforcement (ICE) brought parts of downtown Portland to a standstill Sunday, culminating in a tense confrontation with federal officers outside a detention facility.
